William Blair & Company
EGRX

William Blair & Company’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

William Blair & Company’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,952
Closed -$48.3K – 1902
2024
Q3 		$48.3K Sell
12,952
-148
-1% -$706 ﹤0.01% 1638
2024
Q2 		$73.4K Sell
13,100
-1,050
-7% -$4.57K ﹤0.01% 1552
2024
Q1 		$74.1K Sell
14,150
-3,215
-19% -$17.6K ﹤0.01% 1550
2023
Q4 		$90.8K Sell
17,365
-5,085
-23% -$50.2K ﹤0.01% 1516
2023
Q3 		$354K Sell
22,450
-1,825
-8% -$32.8K ﹤0.01% 1164
2023
Q2 		$472K Sell
24,275
-2,350
-9% -$55.8K ﹤0.01% 1072
2023
Q1 		$755K Sell
26,625
-12,547
-32% -$372K ﹤0.01% 909
2022
Q4 		$1.14M Sell
39,172
-3,185
-8% -$101K 0.01% 783
2022
Q3 		$1.12M Hold
42,357
– – 0.01% 783
2022
Q2 		$1.88M Sell
42,357
-20
-0% -$919 0.01% 656
2022
Q1 		$2.1M Sell
42,377
-8,125
-16% -$390K 0.01% 684
2021
Q4 		$2.57M Sell
50,502
-1,325
-3% -$68.7K 0.01% 652
2021
Q3 		$2.89M Sell
51,827
-2,160
-4% -$106K 0.01% 605
2021
Q2 		$2.31M Sell
53,987
-5,150
-9% -$213K 0.01% 673
2021
Q1 		$2.47M Buy
59,137
+9,432
+19% +$438K 0.01% 619
2020
Q4 		$2.31M Buy
49,705
+617
+1% +$28.9K 0.01% 612
2020
Q3 		$2.08M Sell
49,088
-4,292
-8% -$188K 0.01% 573
2020
Q2 		$2.56M Buy
53,380
+50
+0.1% +$2.5K 0.01% 503
2020
Q1 		$2.45M Sell
53,330
-5,240
-9% -$263K 0.02% 473
2019
Q4 		$3.52M Sell
58,570
-2,005
-3% -$120K 0.02% 478
2019
Q3 		$3.43M Buy
60,575
+836
+1% +$47K 0.02% 462
2019
Q2 		$3.33M Sell
59,739
-1,450
-2% -$75.6K 0.02% 462
2019
Q1 		$3.09M Buy
61,189
+150
+0.2% +$6.67K 0.02% 455
2018
Q4 		$2.46M Sell
61,039
-10,705
-15% -$552K 0.02% 478
2018
Q3 		$4.97M Sell
71,744
-175
-0.2% -$13.3K 0.03% 372
2018
Q2 		$5.44M Sell
71,919
-2,950
-4% -$186K 0.04% 334
2018
Q1 		$3.94M Sell
74,869
-3,760
-5% -$219K 0.03% 403
2017
Q4 		$4.2M Buy
78,629
+7,054
+10% +$393K 0.03% 397
2017
Q3 		$4.27M Sell
71,575
-7,460
-9% -$451K 0.03% 374
2017
Q2 		$6.24M Buy
79,035
+5,340
+7% +$437K 0.05% 298
2017
Q1 		$5.65M Sell
73,695
-6,760
-8% -$503K 0.05% 299
2016
Q4 		$6.38M Sell
80,455
-2,200
-3% -$160K 0.06% 264
2016
Q3 		$5.79M Buy
82,655
+16,350
+25% +$906K 0.05% 286
2016
Q2 		$2.57M Buy
66,305
+925
+1% +$38.5K 0.02% 422
2016
Q1 		$2.65M Buy
65,380
+16,280
+33% +$1.03M 0.02% 395
2015
Q4 		$4.35M Buy
49,100
+1,346
+3% +$106K 0.04% 317
2015
Q3 		$3.54M Buy
47,754
+3,934
+9% +$327K 0.03% 385
2015
Q2 		$3.54M Sell
43,820
-56,405
-56% -$3.67M 0.01% 1160
2015
Q1 		$4.2M Buy
+100,225
New +$2.84M 0.01% 1087

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

William Blair & Company's EGRX Position: Q4 2024 in Review

William Blair & Company sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 12,952 shares — an estimated $48.3K sold.

William Blair & Company first reported a position in EGRX in Q1 2015 and held it in 39 quarters. The position peaked at $6.38M in Q4 2016. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • William Blair & Company reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • William Blair & Company sold 12,952 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $48.3K.
  • William Blair & Company first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 39 quarters.
  • William Blair & Company's Eagle Pharmaceuticals, Inc. position peaked at $6.38M in Q4 2016.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on William Blair & Company's 13F filing for Q4 2024, filed 12 Feb 2025.